

Point Prevalence Survey of Antimicrobial Use and Healthcare-Associated Infections in Belgian Acute Care Hospitals: Results of the Global-PPS and ECDC-PPS 2017

ADDITIONAL FILE 2

Table S2: Overview of antibiotic (J01) prescriptions by antibiotic subclass (ATC level 4) and by indication, total results for Global and ECDC-PPS 2017 (Belgium, acute care hospitals)

ATC-code (level 4)	Name	Number of prescriptions (% J01)					
		Total	CAI	HAI	LAI	MP	SP
J01	Antibacterials for systemic use	8448	4511	2057	229	396	1033
J01AA	Tetracyclines	55 (0.7%)	30 (0.7%)	19 (0.9%)	2 (0.9%)	1 (0.3%)	0
J01BA	Amphenicols	3 (0.04%)	1 (0.02%)	0	0	0	0
J01CA	Penicillins with extended spectrum	562 (6.7%)	382 (8.5%)	111 (5.4%)	19 (8.3%)	32 (8.1%)	6 (0.6%)
J01CE	Beta-lactamase sensitive penicillins	49 (0.6%)	33 (0.7%)	4 (0.2%)	0	11 (2.8%)	1 (1.0%)
J01CF	Beta-lactamase resistant penicillins	233 (2.8%)	133 (2.9%)	89 (4.3%)	1 (0.4%)	1 (0.3%)	4 (0.4%)
J01CG	Beta-lactamase inhibitors	7 (0.08%)	4 (0.9%)	3 (0.1%)	0	0	0
J01CR	Combinations of penicillins, incl. beta-lactamase inhibitors	2724 (32.3%)	1814 (40.2%)	619 (30.1%)	91 (39.7%)	49 (12.4%)	91 (8.8%)
J01DB	First-generation cephalosporins	737 (8.7%)	13 (0.3%)	4 (0.2%)	1 (0.4%)	3 (0.8%)	715 (69.2%)
J01DC	Second-generation cephalosporins	347 (4.1%)	193 (4.3%)	82 (4.0%)	13 (5.7%)	5 (1.3%)	48 (4.6%)
J01DD	Third-generation cephalosporins	554 (6.6%)	359 (8.0%)	153 (7.4%)	24 (10.5%)	6 (1.5%)	4 (0.4%)
J01DE	Fourth-generation cephalosporins	101 (1.2%)	44 (1.0%)	53 (2.6%)	2 (0.9%)	2 (0.5%)	0
J01DF	Monobactams	12 (0.1%)	3 (0.07%)	5 (0.3%)	1 (0.4%)	0	2 (0.2%)
J01DH	Carbapenems	323 (3.8%)	112 (2.5%)	193 (9.4%)	13 (5.7%)	1 (0.3%)	1 (0.1%)
J01EA	Trimethoprim and derivates	8 (0.09%)	2 (0.04%)	1 (0.05%)	1 (0.4%)	4 (1.0%)	0
J01EB	Short-acting sulfonamides	1 (0.01%)	0	1 (0.05%)	0	0	0
J01EC	Intermediate-acting sulfonamides	8 (0.09%)	1 (0.02%)	4 (0.2%)	1 (0.4%)	2 (0.5%)	0
J01EE	Combinations of sulfonamides and trimethoprim	265 (3.1%)	72 (1.6%)	57 (2.8%)	2 (0.9%)	109 (27.5%)	9 (0.9%)
J01FA	Macrolides	306 (3.6%)	147 (3.3%)	21 (1.0%)	6 (2.6%)	77 (19.4%)	1 (0.1%)
J01FF	Lincosamides	237 (2.8%)	158 (3.5%)	36 (1.8%)	4 (1.7%)	4 (1.0%)	34 (3.3%)
J01GB	Aminoglycosides	123 (1.5%)	70 (1.6%)	40 (1.9%)	3 (1.1%)	6 (1.5%)	1 (0.1%)
J01MA	Fluoroquinolones	1131 (13.4%)	658 (14.6%)	315 (15.3%)	37 (16.2%)	36 (9.1%)	61 (5.9%)
J01MB	Other quinolones	1 (0.01%)	0	1 (0.05%)	0	0	0
J01RA	Combinations of antibacterials	23 (0.3%)	15 (0.3%)	3 (0.1%)	0	3 (0.8%)	0
J01XA	Glycopeptide antibacterials	239 (2.8%)	83 (1.8%)	145 (7.0%)	4 (1.7%)	0	3 (0.3%)
J01XB	Polymyxins	15 (0.2%)	7 (0.2%)	7 (0.3%)	0	1 (0.3%)	0
J01XD	Imidazole derivatives	202 (2.4%)	112 (2.5%)	42 (2.0%)	0	2 (0.5%)	38 (3.7%)
J01XE	Nitrofurantoin derivatives	131 (1.6%)	49 (1.1%)	26 (1.3%)	4 (1.7%)	31 (7.8%)	0
J01XX	Other antibacterials	51 (0.6%)	16 (0.4%)	23 (1.1%)	0	10 (2.5%)	14 (1.4%)

ATC= Anatomical Therapeutic Chemical classification system, CAI = community-acquired infections, ECDC = European Centre for Disease Prevention and Control, HAI = healthcare-associated infections, LAI = Infection present on admission from long-term care facility or Nursing Home, MP = medical prophylaxis, SP = surgical prophylaxis